AN2 Therapeutics (ANTX) Change in Acquisitions & Divestments (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $11.0 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 65.1% year-over-year to $11.0 million in Q1 2026; TTM through Mar 2026 was $54.0 million, a 49.33% decrease from a year earlier, with the FY2025 full-year figure at $74.5 million, down 26.49% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $11.0 million, down from $15.5 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for ANTX reached as high as $31.5 million in Q1 2025 and fell as low as $10.0 million in Q3 2025.
• Historically, Change in Acquisitions & Divestments has averaged $20.5 million across 5 years, with a median of $20.2 million in 2023.
• Across the five-year window, Change in Acquisitions & Divestments soared 66.28% in 2023 and sank 65.1% in 2026, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $23.5 million in 2022, then slipped by 13.83% to $20.2 million in 2023, then decreased by 13.58% to $17.5 million in 2024, then decreased by 11.43% to $15.5 million in 2025, then declined by 29.08% to $11.0 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $11.0 million in Q1 2026, $15.5 million in Q4 2025, and $10.0 million in Q3 2025.